ivonvstr

The tweets posted here are artistic work of fiction and falsehood, and are never investment or medical advice. Only a fool would take my tweets as fact.

[ivonvstr @borisschmalz]

@pawcio2009 😹

[ivonvstr @borisschmalz]

@avidresearch Not Duggan size but at least also not a sale .)

[ivonvstr @borisschmalz]

@rivatez was peak time for singularity university at nasa ames

[ivonvstr @borisschmalz]

@RayneWothbaum @PersimmonTI @jq1234t @AppleHelix 😁

[ivonvstr @borisschmalz]

@_le_Lounge Moving today

[ivonvstr @borisschmalz]

@PersimmonTI What if it works really well :)

[ivonvstr @borisschmalz]

@PersimmonTI 😂

[ivonvstr @borisschmalz]

@JacobPlieth Thank you for Jacob

[ivonvstr @borisschmalz]

@JacobPlieth No OS HR data yet

[ivonvstr @borisschmalz]

@JacobPlieth putamig right after ivo

[ivonvstr @borisschmalz]

@JacobPlieth Will be an interesting day

[ivonvstr @borisschmalz]

@JacobPlieth Interesting re $smmt thank you

[ivonvstr @borisschmalz]

@doctorcfa I mentioned yesterday .)

[ivonvstr @borisschmalz]

@But_The_Comps Time will tell

[ivonvstr @borisschmalz]

@bioinvestor24 Sorry

Perhaps more data on 15th

(I know nothing)

[ivonvstr @borisschmalz]

@bioinvestor24 Source

https://t.co/2sJYArTR8e

[ivonvstr @borisschmalz]

@bioinvestor24 hazard ratio (HR) of 0.51 (95% CI: 0.38, 0.69; p<0.0001)

[ivonvstr @borisschmalz]

@bioinvestor24 Great question

[ivonvstr @borisschmalz]

@monaco_biotech You're still up and quick to post :)

[ivonvstr @borisschmalz]

$SMMT

Overall Survival Analysis From HARMONi-2: Ivonescimab vs Pembrolizumab as First-Line Treatment for PD-L1-Positive NSCLC

September 15th